The Day Three Major FMT × Immunotherapy Trials Landed Together in Nature Medicine — Reshaping Cancer Immunotherapy with the Gut Microbiome | Making Cancer Immunotherapy Work with FMT, Vol. 1
In April 2026, Nature Medicine Vol. 32 No. 4 published three FMT-plus-immunotherapy trials in a single issue: 80% ORR in NSCLC, and a doubling of progression-free survival in metastatic RCC (24.0 vs 9.0 months, HR 0.50). But the deeper significance lies not in the numbers — it is the shared mechanistic finding that responders selectively lost their own deleterious bacteria, rather than acquiring beneficial bacteria from the donor. Volume 1 of our series surveys all three trials and what their simultaneous publication means.
